When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
So, you’re looking to get better at coding with Python, and maybe you’ve heard about LeetCode. It’s a pretty popular place to practice coding problems, especially if you’re aiming for tech jobs.
Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.
After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...
Among the myriad abilities that humans possess, which ones are uniquely human? Language has been a top candidate at least since Aristotle, who wrote that humanity was “the animal that has language.” ...
The Enhanced Reconsideration System (ERS) is a production-grade AI memory management library designed to transform stateless AI agents into stateful ones. It integrates asynchronous promise chains, ...
In AI research, progress is often equated with size. But a small team at Samsung’s AI lab in Montreal has taken another approach that is proving to show great promise. Their new Tiny Recursive Model ...
Hosted on MSN
Where Will Recursion Pharmaceuticals Be in 5 Years?
Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results